Jun. 3 at 8:40 PM
$TMDX
Still valued like a medtech. It should be valued like healthcare infrastructure.
~
$750M revenue today. If revenue reaches
$2.5B by 2030 with 30% operating margins, that's ~
$750M operating income. After tax, ~
$600M net income. On ~40M shares, that's ~
$15 EPS.
Now add the moat: OCS + NOP + aviation network + data + transplant center relationships.
At 35x EPS, that's a
$525 stock.
Most see a device company. I see the infrastructure layer of organ transplantation.
